Related Experiment Videos
Long-term effects of azathioprine therapy for juvenile rheumatoid arthritis
1Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Insights
Azathioprine (AZA) effectively treats juvenile rheumatoid arthritis (JRA) in children, showing clinical improvement in 62.5% of patients. This immunosuppressive drug offers a well-tolerated, steroid-sparing option for refractory JRA cases.
Area of Science:
- Pediatric Rheumatology
- Immunosuppressive Therapy
- Clinical Pharmacology
Background:
- Juvenile rheumatoid arthritis (JRA) poses risks of disability, growth issues, and systemic complications.
- Current treatments including NSAIDs and DMARDs may be insufficient for some JRA patients.
- Corticosteroid dependence is common in children with refractory JRA.
Purpose of the Study:
- To evaluate the efficacy of azathioprine (AZA) in treating pediatric patients with JRA.
- To assess the adverse effects associated with AZA therapy in this population.
- To determine AZA's potential as a steroid-sparing agent for JRA.
Main Methods:
- Retrospective analysis of medical records for 24 children with JRA treated with oral AZA (1988-1998).
- Patients had prior treatment with NSAIDs and/or DMARDs; 21 were corticosteroid-dependent.
- Dosing, duration of treatment, and follow-up periods were recorded.
Main Results:
- Clinical improvement observed in 62.5% (15/24) and remission in 37.5% (9/24) of patients.
- AZA reduced corticosteroid dosage by over 50% in 7 children and allowed complete discontinuation in 8.
- No side effects occurred at doses of 1-3 mg/kg/day; overdose (6 mg/kg/day) led to pancytopenia and infection, resolving with dose reduction.
Conclusions:
- Azathioprine (AZA) is an effective treatment for JRA.
- AZA demonstrates significant steroid-sparing capabilities in pediatric patients.
- The drug is well-tolerated at appropriate dosages for JRA refractory to other therapies.
Background And Purpose:
Juvenile rheumatoid arthritis (JRA) can result in disability, growth disturbance, and systemic complications. This study investigated the efficacy and adverse effects of azathioprine (AZA) therapy in children with JRA.
Methods:
Data from the medical records of 24 children with JRA treated with oral AZA during the period from 1988 to 1998 were retrospectively analyzed. All 24 patients had received two or more nonsteroidal anti-inflammatory drugs (NSAIDs) and 12 had received disease-modifying antirheumatic drugs (DMARDs) prior to the start of AZA. Of the 24 patients, 21 were corticosteroid-dependent prior to the onset of AZA therapy. The indication for AZA therapy was lack of efficacy of the current treatment regimen. The initial and maximal doses of AZA averaged 1.7 mg.kg-1.d-1 (range, 1-3 mg. kg-1.d-1) and 1.9 mg.kg-1.d-1 (range, 1-6 mg.kg-1.d-1), respectively. The mean duration of treatment was 13 months (range, 4-37 mo). The mean duration of follow-up was 45 months (range, 7-137 mo) from the start of AZA therapy.
Results:
Fifteen children (62.5%) showed clinical improvement, while the other nine (37.5%) achieved clinical remission. AZA treatment resulted in a more than 50% reduction in the required corticosteroid dose in seven children and complete discontinuation of corticosteroid administration in eight children. None of the patients treated with AZA doses of 1 to 3 mg.kg-1.d-1 developed AZA-related side-effects. Two patients suffered from AZA-related adverse effects due to AZA overdose (6 mg.kg-1.d-1). Both experienced pancytopenia and disseminated infection, which resolved following reduction of the AZA dose to 3 mg.kg-1.d-1.
Conclusions:
AZA is an effective and well-tolerated steroid-sparing agent for JRA refractory to NSAIDs or DMARDs.